CuradermBEC5 for Skin Cancers, Is It? An Overview
Tania Robyn Chase
DOI: 10.4236/jct.2011.25099   PDF    HTML   XML   16,825 Downloads   28,389 Views   Citations


Skin cancer incidence is increasing at alarming rates and is considered by some as an epidemic. Its incidence is higher than all other cancers combined. The developments of new treatments have not parallelled the increased incidences of this disease. A variety of treatments are available with differing outcomes. More recently a novel topical treatment, consisting of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from plant material, has been described that claims to have many advantages over the currently used skin cancer therapies. This review investigates such claims.

Share and Cite:

T. Chase, "CuradermBEC5 for Skin Cancers, Is It? An Overview," Journal of Cancer Therapy, Vol. 2 No. 5, 2011, pp. 728-745. doi: 10.4236/jct.2011.25099.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] H. W. Rogers, N. A. Weinstock, A. R. Harris, M. R. Hinckley, S. R. Feldman, A. B. Fleischer and B. M. Coldiron, “Incidence Estimate of Nonmelanoma Skin Cancer in the United States,” Archives of Dermatology, Vol. 146, No. 3, 2010, pp. 283-287. doi:10.1001/archdermatol.2010.19
[2] B. E. Cham, “Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports,” International Journal Clinical Medicine, Vol. 2, No. 4, 2011, pp. 473-477. doi:10.4236/ijcm.2011.24080
[3] M. B. Lens and M. Dawes, “Epidemiological Trends of Cutaneous Malignant Melanoma: Incidence of Cutaneous Malignant Melanoma,” British Journal of Dermatology, Vol. 150, 2004, pp. 179-185. doi:10.1111/j.1365-2133.2004.05708.x
[4] L. A. E. Sussman and D. F. Liggins, “Incompletely Excised Basal Cell Carcinoma a Management Dilemma?” Australian and New Zealand Journal of Surgery, Vol. 66, No. 5, 1996, pp. 276-278. doi:10.1111/j.1445-2197.1996.tb01184.x
[5] B. E. Cham, M. Gilliver and L. Wilson, “Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum L.,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[6] B. E. Cham and B. Daunter, “Solasodine Glycosides. Selective Cytoxicity for Cancer Cells and Inhibition of Cytotoxicity by Rhamnose in Mice with Sarcoma 180,” Cancer Letters, Vol. 55, No. 3, 1990, pp. 221-225. doi:10.1016/0304-3835(90)90122-E
[7] B. E. Cham, “Monograph on the Compound BEC,” Drugs of the Future, Vol. 13, 1988, pp. 714-716.
[8] B. E. Cham and L. Wilson, “HPLC of Glycoalkaloids from Solanum sodomaeum,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[9] B. E. Cham, “Eggplant Wins War against Skin Cancer. Conquest on the Horizon for Internal Cancers?” Book, in preparation.
[10] P. G. Jones and G. R. Fenwick, “The Glycoalkaloid Content of Some Edible Solanaceous Fruits and Potato Products,” Journal Science Food Agriculture, Vol. 32, No. 4, 1981, pp. 419-421. doi:10.1002/jsfa.2740320418
[11] P. Vijayan, V. Kumar, S. Dhanaraj, S. A. Badami and B. Suresh, “In Vitro Cytotoxicity and Anti-tumour Properties of the Total Alkaloid Fraction of Unripe Fruits of Solanum Pseudocapsicum,” Pharmaceutical Biology, Vol. 40, 2002, pp. 456-460. doi:10.1076/phbi.40.6.456.8444
[12] T. Nakamura, C. Komori, Y. Lee, F. Hashinoto, S. Yahara, T. Nohara and A. Ejina, “Cytotoxic Activities of Solanum Steroidal Glycosides,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 4, 1996, pp. 564-566. doi:10.1248/bpb.19.564
[13] K. W. Kuo, S. H. Hsu, Y. P. Li, W. L. Lin, L. F. Liu, L. C. Chang, C. C. Lin, C. N. Lin and H. M. Sheu, “Anticancer Activity Evaluation of the Solanum Glycoalkaloid Solamargine. Triggering Apoptosis in Human Hepatoma Cells,” Biochemistry Pharmacology, Vol. 60, No. 1-2, 2000, pp. 1865-1873. doi:10.1016/S0006-2952(00)00506-2
[14] L. C. Chang, T. R. Tsai, J. J. Wang, C. N. Lin and K. W. Kuo, “The Rhamnose Moiety of Solamargine Plays a Crucial Role in Triggering Cell Death by Apoptosis,” Biochemical and Biophysical Research Communications, Vol. 242, No. 1, 1998, pp. 21-25.
[15] S. Badami, S. A. Manohara Reddy, E. P. Kumar, P. Vijayan and B. Suresh, “Antitumour Activity of Total Alkaloid Fraction of Solanum Pseudocapsicum Leaves,” Phytotherapy Research, Vol. 17, No. 9, 2003, pp. 1001-1004. doi:10.1002/ptr.1229
[16] A. Esteves-Souza, T. M. Silva and C. C. F. Alves, “Cytotoxic Activities against Ehrlich Carcinoma and Human K562 Leukaemia of Alkaloids and Flavonoid from Two Solanum Species,” Journal of Brazil Chemistry Society, Vol. 13, No. 6, 2002, pp. 838-842. doi:10.1590/S0103-50532002000600017
[17] L. A. Chami, R. Méndez, B. Chataing, J. O’Callaghan, A. Usubillaga and L. LaCruz, “Toxicological Effects of α-Solamargine in Experimental Animals,” Phytotherapy Research, Vol. 17, No. 3, 2003, pp. 254-258. doi:10.1002/ptr.1122
[18] C. A. Hall, T. Hobby and M. Cipollini, “Efficacy and Mechanisms of α-Solasonine-and α-Solamargine-Induced Cytolysis on Two Strains of Trypanosoma cruzi,” Journal of Chemical Ecology, Vol. 32, No. 11, 2006, pp. 2405-2416. doi:10.1007/s10886-006-9153-5
[19] R. Verpoorte, “Exploration of Nature’s Chemodiversity: The Role of secondary Metabolites as Leads in Drug Development,” Drug Discovery Today, Vol. 3, No. 5, 1998, pp. 232-238. doi:10.1016/S1359-6446(97)01167-7
[20] J. G. Roddick, A. L Ryrenber and M. Weissenber, “Membrane-Disrupting Properties of the Steroidal Glycoalkaloids Solasonine and Solamargine,” Phytochemistry, Vol. 29, No. 5, 1990, pp. 1513-1518. doi:10.1016/0031-9422(90)80111-S
[21] K. W. Kuo and C. N. Lin, “Pharmacological Composition for Treating Cancer Cells,” United States Patent 6, 1999, pp. 214-803.
[22] Solbec Pty Ltd. hhtp://
[23] C. Amalfi, “The Little Mouse Who Wouldn’t Say Die,” Cosmos Magazine, 2006, p. 471.
[24] B. E. Cham, “Plants Yield Skin Cancer Cure,” Austral Technology Review, Vol. 2, 1989, p. 53.
[25] R. Evans, B. E. Cham and B. Daunter, “Letter to the Editor,” Your Pharmacy, Vol. January, 1989, p. 1.
[26] B. E. Cham, “Curaderm (Antineoplastic) Launched in Australia,” Drug News and Perspectives, Vol. 2, No. 2, 1989, p. 112.
[27] B. E. Cham, “Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers,” Research Journal Biological Science, Vol. 2, No. 7, 2007, pp. 749-761.
[28] A. K. Taraphdar, M. Roy and R. K. Bhattacharya, “Natural Products as Inducers of Apoptosis: Implication for Cancer Therapy and Prevention,” Current Science, Vol. 80, No. 11, 2001, pp. 1387-1395.
[29] B. E. Cham, “Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and necrosis. Treatment for Skin Cancer and Hope for Internal Cancers,” Research Journal Biological Science, Vol. 2, No. 4, 2007, pp. 503-514.
[30] B. E. Cham, “Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides,” Research Journal Biological Sciences, Vol. 3, 2008, pp. 1008-1017.
[31] L. Y. Shiu, L. C. Chang, C. H. Liang, Y. S. Huang, H. M. Sheu and K. W. Kuo, “Solamargine Induces Apoptosis and Sensitizes Breast Cancer Cells to Cisplatin,” Food Chemistry Toxicology, Vol. 45, No. 11, 2007, pp. 2155-2164. doi:10.1016/j.fct.2007.05.009
[32] B. Daunter and B. E. Cham, “Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells,” Cancer Letters, Vol. 55, No. 3, 1990, pp. 209-220. doi:10.1016/0304-3835(90)90121-D
[33] X. Li, Y. Zhao, W. K. K. Wu, S. Liu, M. Cui and H. Lou, “Solamargine Induces Apoptosis Associated with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U20S Cells,” Life Science, Vol. 88, No. 7-8, 2011, pp. 314-321. doi:10.1016/j.lfs.2010.12.006
[34] B. E. Cham, “Solasodine Glycosides as Anti-Cancer Agents: Pre-Clinical and Clinical Studies,” Asia Pacific Journal Pharmacology, Vol. 9, No. 2, 1994, pp. 113-118.
[35] L. Y. Shiu, C. H. Liang, Y. S. Huang, H. M. Sheu and K. W. Kuo, “Downregulation of HER2/neu Receptor by Solamargine Enhances Anticancer Drug-Mediated Cytotoxicity in Breast Cancer Cells with High-Expressing HER2/neu,” Cell Biology and Toxicology, Vol. 24, No. 1, 2008, pp. 1-10. doi:10.1007/s10565-007-9010-5
[36] C. Paquet, A. T. Sané, M. Beauchemin and R. Bertrand, “Caspase-and Mitochondrial Dysfunction Dependent Mechanisms of Lysosomal Leakage and Cathepsin B Activation in DNA Damage-Induced Apoptosis,” Leukemia, Vol. 19, 2005, pp. 784-791. doi:10.1038/sj.leu.2403717
[37] B. E. Cham and T. R. Chase, “Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells, Do They Also Prime the Immune System Resulting in Long Term Protection Against Cancer?” Planta Medica, in Press.
[38] B. E. Cham, “The Eggplant Cancer Cure. A Treatment for Skin Cancer and New Hope for Other Cancers from Nature’s Pharmacy,” Smart Publications, Petaluma, 2007, p. 122.
[39] L. Sun, Y. Zhao, H. Yuan, X. Li, A. Cheng and H. Lou, “Solamargine, a Steroidal Alkaloid Glycoside, Induces Oncosis in Human K562 Leukemia and Squamous Cell Carcinoma KB Cells,” Cancer Chemotherapy and Pharmacology, Vol. 65, No. 4, 2010, pp. 1125-1130.
[40] I. Davis and A. Dowling, “Side Effects of Chemotherapy,” Cancer Council Victoria, 2010.
[41] B. E. Cham, “Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers,” Research Journal Biological Science. Vol. 2, No. 4, 2007, pp. 503-514.
[42] Basic Cell Cercinoma Information.
[43] B. E. Cham and B. Daunter, “Topical Treatment of Pre-Malignant and Malignant Skin Cancers with Curaderm,” Drugs of Today, Vol. 26, 1990, pp. 55-58.
[44] B. E. Cham, B. Daunter and R. Evans, “Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentration of a standard mixture of Solasodine Glycosides,” Cancer Letters, Vol. 59, No. 3, 1991, pp. 183-192.
[45] B. Schuell, T. Greenberger, G. V. Kornek, N. Durran, D. Depisch, F. Lang, B. Schneeweiss and W. Scheithauer, “Side Effects during Chemotherapy Predict Tumour Response in Advanced Colorectal Cancer,” British Journal Cancer, Vol. 93, 2005, pp. 744-748. doi:10.1038/sj.bjc.6602783
[46] B. E. Cham and H. M. Meares, “Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man,” Cancer Letters, Vol. 36, No. 2, 1987, pp. 111-118. doi:10.1016/0304-3835(87)90081-4
[47] B. E. Cham, “Efficacy and Mode of Action of Solasodine Glycosides (BEC) on Cancer Cells,” Proceedings of the 4th Oceania Symposium on Complementary Medicine, Mark S. Walker, Ed., Bio Concepts Publishing, Brisbane, 1993, pp. 41-51.
[48] B. E. Cham, B. Daunter and R. Evans, “Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides,” Cancer Letters, Vol. 59, No. 3, 1991, pp. 183-192. doi:10.1016/0304-3835(91)90140-D
[49] B. E. Cham, “Solasodine Glycosides: A New Modality for Cancer,” Proceeding of 2nd Oceania Symposium, Mark S. Walker, Ed., Bio Concepts Publishing, Brisbane, 1991, pp. 30-36.
[50] M. Ono, K. Nishimura, K. Suzuki, T. Fukushima, K. Igoshi, H. Yoshimitsu, T. Ikeda, and T. Nohara, “Steroidal Glycosides from the underground Parts of Solanum Sodomaeum,” Chemical & Pharmaceutical Bulletin, Vol. 54, No. 2, 2006, pp. 230-233. doi:10.1248/cpb.54.230
[51] L. F. Liu, C. H. Liang, L. Y. Shiu, W. L. Lin, C. C. Lin and K. W. Kuo, “Action of Solamargine on Human Lung Cancer Cells-Enhancement of the Susceptibility of Cancer Cells to TNFs,” FEBS Letter, Vol. 577, No. 1-2, 2004, pp. 67-74. doi:10.1016/j.febslet.2004.09.064
[52] K. R. Lee, N. Kozukue, J. S. Han, J. H. Park, E. Y. Chang, E. J. Back, J. S. Chang and M. Friedman, “Glycoalkaloids and Metabolites Inhibit the Growth of Human Colon (HT29) and Liver (HepG2) Cancer Cells,” Journal Agriculture Food Chemistry, Vol. 52, No. 10, 2004, pp. 2832-2839. doi:10.1021/jf030526d
[53] B. Chataing, N. B. Christancho and A. Usubillaga, “Topical Treatment of Herpes Simplex, Herpes Zoster and Genital Herpes with a Mixture of Solanaceous Glycoalkaloids,” MedULA. Universidad de Los Andes, Vol. 7. 1998, pp. 30-34.
[54] N. Walsh, “Promising Topical Therapy for Actinic Keratoses—Brief Article,” International Medical News Group, Morristown, 2005.
[55] S. Punjabi, I. Cook, P.Kersey, R. Marks, A. Finlay, G. Sharpe et al., “A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma,” European Academy Dermatology Venereol, Vol. 14, 2000, pp. 47-60.
[56] S. Punjabi, L. J. Cook, P. Kersey, R. Marks and R. Cerio, “Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study,” International Journal Dermatology, Vol. 47, 2008, pp. 78-82.
[57] B. E. Cham, “Combination Therapies with Intralesion Injection and Topical Application of Solasodine Rhamnosyl Glycosides (BEC) Rapidly Remove Large Skin Cancers,” In preparation.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.